Instruction video on reconstitution of Obizur

Information On Dose Calculation for OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence]

Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Atopic Dermatitis and Alopecia Areata.

Important Risk Minimization information for healthcare professionals prescribing Olumiant for the treatment of Rheumatoid Arthritis.

Olumiant 2 mg and 4 mg Film-Coated Tablets Patient Alert Card containing important safety information for patients.

Educational Material for Healthcare Professionals to ensure safe use of Onpattro in the home setting.

Educational Material for patients for safe use of Onpattro in the home.

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with nivolumab or nivolumab in combination with ipilimumab. This card was updated in September 2022 (administrative updates only). Changes to the card include design/editorial updates and addition of the Northern Ireland emc url.

This card is part of the marketing authorisation for Opdualag (nivolumab and relatlimab) and contains important safety information that you need to be aware of. Please also ensure that you carry this card with you at all times to inform any healthcare professional treating you (e.g., emergency department personnel) that you are receiving treatment with nivolumab and relatlimab.

HOME INFUSION PATIENT DIARY

HOME INFUSION PATIENT MANUAL

Patient reminder card

INFORMATION PACK FOR HEALTHCARE PROFESSIONALS

It is important that you report immediately to your prescribing doctor any pregnancy or side effects that may occur during treatment with Opsumit.

This checklist will efficiently guide your consultation with women asking for Ovesse 1mg/g Vaginal Cream or asking for help for their vaginal atrophy symptoms. It may also be used as the basis for an online pharmacy screening algorithm. The checklist should be used by Pharmacy team members who have read and understood the Ovesse 1mg/g Vaginal Cream Pharmacy Guide and have access to the Summary of Product Characteristics and Patient Information Leaflet.

This Pharmacy Guide and Checklist is part of a package of materials created by Aspen Pharmacare UK Limited to support Pharmacies implement the supply of Ovesse 1mg/g Vaginal Cream. It includes important information to enable community and online Pharmacies to identify women to whom they can supply Ovesse and the advice they should share to support the appropriate use of Ovesse. Some women will need to be referred to their GP to confirm their suitability for supply and this Pharmacy Guide, incorporating the Pharmacy Checklist, will help identify such cases.

A patient guide to OZURDEX therapy Ref: UK-OZU-220475 DOP: Feb 2023